Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051308 | 0.80 | TLR7 (0.38) | KDM4ENPC1MAPK1RAB9ATLR7 | |
| SCHEMBL23991751 | 0.72 | KDM4E (0.34) | KDM4ENPC1MAPK1RAB9A | |
| SCHEMBL5160393 | 0.72 | TBXAS1 (0.45) | CYP11B1CYP11B2TBXAS1KDM4EMAPK1 | |
| SCHEMBL30962408 | 0.72 | KDM4E (0.39) | KDM4ENPC1MAPK1RAB9AALDH1A1 | |
| SCHEMBL15825088 | 0.68 | KDM4E (0.46) | KDM4ENPC1MAPK1RAB9AALDH1A1 | |
| SCHEMBL21810392 | 0.67 | KDM4E (0.42) | KDM4ENPC1MAPK1RAB9AALDH1A1 | |
| SCHEMBL31495484 | 0.66 | OGG1 (0.42) | KDM4ENPC1MAPK1RAB9AALDH1A1 | |
| SCHEMBL3515320 | 0.65 | CYP11B1 (0.41) | CYP11B1CYP11B2KDM4ENPC1RAB9A | |
| SCHEMBL22440094 | 0.65 | KDM4E (0.36) | KDM4ENPC1MAPK1RAB9AALDH1A1 | |
| SCHEMBL938447 | 0.65 | SCN5A (0.54) | KDM4ENPC1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1764098-A1 | Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764099-A2 | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | CTSD, FURIN, CTSL | CYP11B1 4582/4885CYP11B2 4543/4885TBXAS1 4525/4885 |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | CTSD, CTSL, CTSC | CYP11B1 4654/4885CYP11B2 4621/4885TBXAS1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.